Phytotherapy Research · 1997 · 24 citations · 9 references
Veterinary MedicineBiologyInfectious DiseasesInfectious Disease PathologyMycologyParasitologyAnthelmintic PharmacologyParasitic Disease PathogenesisParasitic ProtozoaProtozoal InfectionsProtozoan Host-parasite InteractionsProtozoan PathogenesisAntileishmanial TreatmentParasite Burden ControlSecondary MetabolitesSubcutaneous Drug AdministrationTreatment Of LeishmaniasisTrypanocidal TherapyTrypanosoma Cruzi InfectionTrypanosome Infections
Seventeen extracts and seven secondary metabolites isolated from basidiomycetes were tested in medium culture against promastigote forms of Leishmania spp. and bloodstream forms of Trypanosoma cruzi. Extracts from the culture filtrate or mycelium were generally inactive against the parasites except the Zucoagaricus genus mycelium extract which reduced by 47% the number of bloodstream forms. Striatin A, striatin B and podoscyphic acid exhibited in vitro activity at 10, 5 and 100 μg/mL, respectively. One compound showed activity against bloodstream forms of T. cruzi, the sesquiterpenoid naematolin, lysing the parasites by 79%. BALB/c mice infected with L. amazonensis were treated 3 weeks post-infection with striatin A and striatin B by subcutaneous route for 15 days at 10 mg/kg daily. The reference drug, N-methylglucamine antimonate, administered by subcutaneous injections at 28 mg Sbv/kg/day for 15 days reduced the parasite burden by 71.2% (p <0.05). Subcutaneous administration of straitin A at 10 mg/kg produced a weak decrease of the parasite burdens in the footpad by 17.6%. The treatment with striatin B had no effect and showed higher toxicity than striatin A. © 1997 John Wiley & Sons, Ltd.
9
Alain Fournet, Angel Barrios, Verónica Francisca Loewe Muñoz et al. · Phytotherapy Research · 1994 · 56 citations
Hans‐Jürgen Hecht, Gerhard Höfle, Wölfgang Steglich et al. · Journal of the Chemical Society Chemical Communications · 1978 · 46 citations